ECP
BIIB icon

Empyrean Capital Partners’s Biogen BIIB Stock Holding History

Empyrean Capital Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-225,859
Closed -$79.8M – 66
2018
Q3 		$79.8M Buy
225,859
+50,000
+28% +$17.2M 2.5% 9
2018
Q2 		$51M Buy
175,859
+25,859
+17% +$7.27M 1.62% 18
2018
Q1 		$41.1M Hold
150,000
– – 2.2% 14
2017
Q4 		$47.8M Hold
150,000
– – 2.16% 14
2017
Q3 		$47M Hold
150,000
– – 1.8% 11
2017
Q2 		$40.7M Buy
+150,000
New +$39.7M 1.73% 13

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Empyrean Capital Partners's BIIB Position: Q4 2018 in Review

Empyrean Capital Partners sold out of Biogen (BIIB) in Q4 2018, closing a stake of 225,859 shares — an estimated $79.8M sold.

Empyrean Capital Partners first reported a position in BIIB in Q2 2017 and held it in 6 quarters. The position peaked at $79.8M in Q3 2018. 1,141 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

  • Empyrean Capital Partners reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
  • Empyrean Capital Partners sold 225,859 Biogen shares in Q4 2018, an estimated $79.8M.
  • Empyrean Capital Partners first reported a position in Biogen in Q2 2017 and held it in 6 quarters.
  • Empyrean Capital Partners's Biogen position peaked at $79.8M in Q3 2018.
  • 1,141 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on Empyrean Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.